Literature DB >> 28150349

A national review of the clinical use of group O D- red blood cell units.

Rena Hirani1, Janet Wong1, Perfecto Diaz1, Phillip Mondy1, Chris Hogan1, Peta M Dennington1, Joanne Pink1, David O Irving1.   

Abstract

BACKGROUND: There has been an international decline in the demand for red blood cell (RBC) units. In Australia, there has been a 21% reduction in demand between 2012 and 2015. In contrast, the demand for the "universal" group O D- RBC units is in fact proportionally increasing. STUDY DESIGN AND METHODS: The clinical use of the entire O D- RBC distribution for a 5-week period throughout Australia was reviewed. Fate data on each unit issued (n = 9733) were collected that included the indication and urgency of transfusion, reason for discard, component age, and patient demographics.
RESULTS: A total of 74% of audit forms were returned (n = 7143). The national discard rate of issued units was 7.9%. A total of 6387 units were transfused into an estimated total of 3008 patients (55% males) with median patient age of 67 years and median RBC age of 21 days. Forty-seven percent were transfused to group O D- patients. A total of 17.4% were chosen for specific phenotype requirements, 24.5% of units were transfused close to expiry, and 24.5% were transfused into patients of other ABO groups.
CONCLUSION: The data appear broadly representative of the current transfusion and inventory management practices surrounding the use of group O D- RBC units. Strategies to reduce O D RBC demand include reevaluation of inventory holdings particularly at smaller centers, increasing the panel of phenotyped RBC units across all ABO groups, more regular rotation of units between hospitals to minimize time expiry, and continuing education for promoting transfusion of ABO-identical RBC units.
© 2017 AABB.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28150349     DOI: 10.1111/trf.14012

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

1.  Frequencies and ethnic distribution of ABO and RhD blood groups in China: a population-based cross-sectional study.

Authors:  Jue Liu; Shikun Zhang; Qiaomei Wang; Haiping Shen; Yiping Zhang; Min Liu
Journal:  BMJ Open       Date:  2017-12-03       Impact factor: 2.692

2.  Transfusion of packed red blood cells at the end of shelf life is associated with increased risk of mortality - a pooled patient data analysis of 16 observational trials.

Authors:  Monica S Y Ng; Michael David; Rutger A Middelburg; Angela S Y Ng; Jacky Y Suen; John-Paul Tung; John F Fraser
Journal:  Haematologica       Date:  2018-05-24       Impact factor: 9.941

3.  A Scalable Suspension Platform for Generating High-Density Cultures of Universal Red Blood Cells from Human Induced Pluripotent Stem Cells.

Authors:  Jaichandran Sivalingam; Yu SuE; Zhong Ri Lim; Alan T L Lam; Alison P Lee; Hsueh Lee Lim; Hong Yu Chen; Hong Kee Tan; Tushar Warrier; Jing Wen Hang; Nazmi B Nazir; Andy H M Tan; Laurent Renia; Yuin Han Loh; Shaul Reuveny; Benoit Malleret; Steve K W Oh
Journal:  Stem Cell Reports       Date:  2020-12-10       Impact factor: 7.765

4.  Selection of O-negative induced pluripotent stem cell clones for high-density red blood cell production in a scalable perfusion bioreactor system.

Authors:  SuE Yu; Svetlan Vassilev; Zhong Ri Lim; Jaichandran Sivalingam; Alan Tin Lun Lam; Valerie Ho; Laurent Renia; Benoit Malleret; Shaul Reuveny; Steve Kah Weng Oh
Journal:  Cell Prolif       Date:  2022-03-15       Impact factor: 8.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.